A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

June 19, 2025

Study Completion Date

July 31, 2025

Conditions
Narcolepsy Type 1
Interventions
DRUG

ALKS 2680

Oral tablet of ALKS 2680 for once daily administration

DRUG

Placebo

Oral tablet containing matching placebo for once daily administration

Trial Locations (45)

2113

Alkermes Investigator Site, Macquarie Park

3570

Alkermes Investigational Site, Alken

5042

Alkermes Investigator Site, Bedford Park

5101

Alkermes Investigational Site, Namur

8000

Alkermes Investigational Site, Bruges

19610

Alkermes Investigational Site, Wyomissing

20127

Alkermes Investigational Site, Milan

28036

Alkermes Investigational Site, Madrid

28037

Alkermes Investigational Site, Denver

28043

Alkermes Investigational Site, Madrid

28708

Alkermes Investigational Site, Huntersville

29201

Alkermes Investigational Site, Columbia

30281

Alkermes Investigational Site, Stockbridge

30328

Alkermes Investigational Site, Atlanta

31210

Alkermes Investigational Site, Macon

32789

Alkermes Investigator Site, Winter Park

33000

Alkermes Investigational Site, Bordeaux

33176

Alkermes Investigational Site, Miami

33511

Alkermes Investigational Site, Brandon

Alkermes Investigator Site, Brandon

34295

Alkermes Investigational Site, Montpellier

37134

Alkermes Investigational Site, Verona

40139

Alkermes Investigational Site, Bologna

43017

Alkermes Investigational Site, Dublin

44718

Alkermes Investigator Site, Canton

45227

Alkermes Investigational Site, Cincinnati

45245

Alkermes Investigational Site, Cincinnati

48314

Alkermes Investigator Site, Sterling Heights

48911

Alkermes Investigator Site, Lansing

61637

Alkermes Investigator Site, Peoria

68506

Alkermes Investigator Site, Lincoln

77380

Alkermes Investigational Site, The Woodlands

78229

Alkermes Investigational Site, San Antonio

78731

Alkermes Investigational Site, Austin

80045

Alkermes Investigational Site, Aurora

80918

Alkermes Investigational Site, Colorado Springs

90025

Alkermes Investigational Site, Los Angeles

92705

Alkermes Investigational Site, Santa Ana

94063

Alkermes Investigational Site, Redwood City

94107

Alkermes Investigator Site, San Francisco

07748

Alkermes Investigational Site, Middletown

128 21

Alkermes Investigational Site, Prague

2103 SW

Alkermes Investigational Site, Heemstede

8025 BV

Alkermes Investigational Site, Zwolle

08036

Alkermes Investigational Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY

NCT06358950 - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) | Biotech Hunter | Biotech Hunter